It is our ambition to develop differentiated and innovative medicines which have the potential to make a real difference to society, as well as creating sustainable value for all its stakeholders.
Our strategy is to use our unique Nanobody technology to develop therapeutics in areas of high unmet medical need where Nanobodies offer a clear advantage over existing products and technologies.
To achieve our goals, we employ a hybrid business model where we invest directly in our own development programmes as well as collaborating with pharmaceutical partners at all stages of discovery and development, selected for their expertise and experience in key areas. In addition, we will retain some or all rights to commercialise our products, with the first launch of our wholly-owned Nanobody, caplacizumab, expected in 2018.
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX and has a sponsored level I programme in the US (OTC: ABYLY).
Lies Vanneste - Director Investor Relations
tel: +32 9 262 01 37
For detailed stock information please click here
ABLX: EUR 10.40 (0.03) (+0.29%)
Recent Financial Reports